1) Eerdekens M, Van Hove I, Remmerie B, et al:Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 70:91-100, 2004
2) Fleischhacker WW, Eerdekens M, Karcher K, et al:Treatment of schizophrenia with long-acting injectable risperidone:A 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64:1250-1257, 2003
3) 稲田健,石郷岡純:Risperidone持続性注射剤の有効性と安全性―国内における臨床試験の結果から.臨精薬理 12:1095-1102, 2009
4) 稲垣中,稲田俊也:第22回持続性抗精神病薬の等価換算(その3)―Risperidone長時間作用型注射製剤.臨精薬理 13:1349-1353, 2010
5) 石垣達也:Risperidone long-acting injection(リスパダールコンスタ)を使用した16症例の検討―患者のアドヒアランスを引き出す治療を求めて.聖マリアンナ医学研究誌 10:7-11, 2010
6) Marder SR, Conley R, Ereshefsky L, et al:Clinical guidelines:Dosing and switching strategies for long-acting risperidone. J Clin Psychiatry 64(Suppl 16):41-46, 2003
7) Olivares JM, Rodrigues-Morales A, Diels J, et al:Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain:Results from the electronic Schizophrenia Treatment Adherence Registry(e-STAR). Eur Psychiatry 24:287-296, 2009
8) Schmauss M, Sacchetti E, Kahn JP, et al:Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int Clin Psychopharmacol 22:85-92, 2007
9) 吉村玲児:Risperidone持続性注射剤(RLAI)の基礎と臨床効果・薬物動態.臨精薬理 12:1075-1080, 2009